$ 5.36
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBIT
Target Price
The average target price of CVAC is 5.4 and suggests 1% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
